and development of
new antibiotics and
The Netherlands Antibiotic Development Platform
The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.
NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.
Stay informed on NADP and subscribe to our Update.
An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.
These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.
The World Health Organization’s (WHO) 2020 annual review of the clinical and preclinical antibacterial pipelines evaluates the potential of antibacterial candidates in different stages of development.
For 2021, NADP still has funding available for two Lead Development Vouchers. Application details for these vouchers can be found on the NADP website. The deadline for applications is 15 April 2021.
NADP was off to good start in 2020 with a meeting in January with then Minister Bruno Bruins, together with NCOH and AMR Global, to discuss the wider AMR policy in the Netherlands, and how this could further be strengthened and further contribute at the international level.